RT Journal Article
SR Electronic
T1 Integrated human/SARS-CoV-2 metabolic models present novel treatment strategies against COVID-19
JF Life Science Alliance
JO Life Sci. Alliance
FD Life Science Alliance LLC
SP e202000954
DO 10.26508/lsa.202000954
VO 4
IS 10
A1 Bridget P Bannerman
A1 Jorge Júlvez
A1 Alexandru Oarga
A1 Tom L Blundell
A1 Pablo Moreno
A1 R Andres Floto
YR 2021
UL https://www.life-science-alliance.org/content/4/10/e202000954.abstract
AB The coronavirus disease 2019 (COVID-19) pandemic caused by the new coronavirus (SARS-CoV-2) is currently responsible for more than 3 million deaths in 219 countries across the world and with more than 140 million cases. The absence of FDA-approved drugs against SARS-CoV-2 has highlighted an urgent need to design new drugs. We developed an integrated model of the human cell and SARS-CoV-2 to provide insight into the virus’ pathogenic mechanism and support current therapeutic strategies. We show the biochemical reactions required for the growth and general maintenance of the human cell, first, in its healthy state. We then demonstrate how the entry of SARS-CoV-2 into the human cell causes biochemical and structural changes, leading to a change of cell functions or cell death. A new computational method that predicts 20 unique reactions as drug targets from our models and provides a platform for future studies on viral entry inhibition, immune regulation, and drug optimisation strategies. The model is available in BioModels (https://www.ebi.ac.uk/biomodels/MODEL2007210001) and the software tool, findCPcli, that implements the computational method is available at https://github.com/findCP/findCPcli.